AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05087381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluvoxamine, Bromhexine
Description: The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.
Study NCT05087381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluvoxamine, Cyproheptadine
Description: The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.
Study NCT05087381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Pill
Description: The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.
Study NCT05087381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Niclosamide, Bromhexine
Description: The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.
Study NCT05166941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: creative drama
Description: In the training program, a total of six games were played about the experiences of psychiatric patients. The program was designed to be two game per week for four weeks.
Study NCT05606757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX Dose A
Description: Injection; intramuscular
Study NCT05606757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BOTOX
Description: Placebo
Study NCT05606757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BOTOX
Description: Placebo
Study NCT05606757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX Dose B
Description: Injection; intramuscular
Study NCT05606757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX Dose C
Description: Injection; intramuscular
Study NCT05959343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion
Description: In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
Study NCT06318325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: examination
Description: examination of tendon, muscle joints and injuries
Study NCT05692505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QuadQuik
Description: Invitro diagnostic device
Study NCT06069050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential adolesent left lateral lobe liver transplantation (SALT)
Description: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
Study NCT05174663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond-enriched diet - 1.5 oz
Description: Participants will receive 1.5 oz of almonds consumed as a snack daily for 16 weeks.
Study NCT05174663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond-enriched diet - 2.5 oz
Description: Participants will receive 2.5 oz of almonds consumed as a snack daily for 16 weeks.
Study NCT05174663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control snack
Description: Participants will receive a control snack daily for 16 weeks.
Study NCT05140330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALAPAGE workshop
Description: 7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
Study NCT05140330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control workshop
Description: 3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
Study NCT04595721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hidden object
Description: Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
Study NCT04595721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress ball
Description: Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
Study NCT05421338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 (C-14)
Description: BI 456906 (C-14)
Study NCT05602545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food consumption in periodontal health and disease
Description: To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
Study NCT05602545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: food consumption in periodontal health and disease
Description: To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
Study NCT05063214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle ultrasound evaluation
Description: Muscle ultrasound evaluation will be performed in patients admitted with COVID-19 requiring invasive mechanical ventilation. The measurements of thickness and thickening fraction will occur for diaphragm, abdominal - rectus abdominis, internal oblique, external oblique and transverse abdomen - and parasternal intercostal muscles. Serial measurements of the thickness and echogenicity of the quadriceps femoris muscle will also be performed.
Study NCT05484388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SN2
Description: Investigational device absorption level Normal
Study NCT05484388 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SN2
Description: Investigational device absorption level Normal
Study NCT05484388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SP3
Description: Investigational device absorption level Plus
Study NCT05484388 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SP3
Description: Investigational device absorption level Plus
Study NCT05403190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci SP system
Description: using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
Study NCT05477732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum OLP-01
Description: Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.
Study NCT05477732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in placebo group will supplement with placebo powder per day for 12 weeks.
Study NCT05225064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives to be vaccinated
Description: Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
Study NCT05225064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask
Description: Individuals are given cloth masks
Study NCT05225064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encouragement to wear a mask
Description: Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
Study NCT05225064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccination made more convenient
Description: Vaccines are conducted at the household-level rather than the village-level
Study NCT05225064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social mobilization campaign to be vaccinated
Description: Village-level social mobilization campaign to be vaccinated
Study NCT05862922 — intervention group
Intervention type: DEVICE
Intervention: Analgesia Nosiception İndex Monitoring
Description: ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period.
Study NCT01511822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drospirenone Ethinyl estradiol
Description: Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
Study NCT01511822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone Ethinyl estradiol Myo-inositol
Description: Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
Study NCT01511822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT06624319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine as adjuvent to bupvacaine in tap block
Description: The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block
Study NCT05047874 — intervention group
Intervention type: BEHAVIORAL
Intervention: systemic methylprednisolone
Description: short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
Study NCT06168812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
Study NCT05604924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: virtual reality training for cesarean section
Description: Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
Study NCT05604924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality training for cesarean section
Description: Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
Study NCT05775055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of oral rehydration solutions
Description: Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
Study NCT05682092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WonderLab Collagen Tripeptide Drink
Description: the participant in this arm will use the assigned product 25ml one time, twice a day.
Study NCT05682092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary Drink
Description: the participant in this arm will use the assigned product 25ml one time, twice a day.
Study NCT05838261 — intervention group
Intervention type: PROCEDURE
Intervention: Pharyngeal flap
Description: Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
Study NCT05592054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon guide catheters (BGCs)
Description: MT procedure with Balloon guide catheters (BGCs)
Study NCT05592054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard guide catheter
Description: MT procedure with standard guide catheter
Study NCT06206967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered.
Study NCT06206967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
Study NCT06484036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment strategy
Description: Periodontal treatment sessions (Experimental Group only) (1 to 3 months) after randomization
Study NCT05189626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks
Study NCT05189626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaltonborn mobilizations
Description: Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
Study NCT05584852 — intervention group
Intervention type: OTHER
Description: no intervention
Study NCT06185998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low pressure tracheostomy cannulas
Description: The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure
Study NCT06185998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low pressure tracheostomy cannulas
Description: The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure
Study NCT06185998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plated balloon tracheostomy cannulas
Description: The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure
Study NCT06185998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plated balloon tracheostomy cannulas
Description: The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure
Study NCT05168579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberate practice
Description: As above
Study NCT05172817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advixa (Adalimumab)
Description: Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
Study NCT05172817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advixa (Adalimumab)
Description: Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
Study NCT06550336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
Study NCT05570006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668
Description: Oral Capsule
Study NCT06492980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: triple-branched stent graft
Description: a triple-branched stent graft for aortic arch repairement during surgery
Study NCT06492980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: triple-branched stent graft
Description: a triple-branched stent graft for aortic arch repairement during surgery
Study NCT05808738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic play
Description: therapeutic game will be played to prepare children for hydrotherapy treatment
Study NCT06170775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulp therapy
Description: Pulp capping material
Study NCT06170775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulp therapy
Description: Pulp capping material